Tempest Therapeutics, Inc. (TPST)
0.89
-0.02
(-2.08%)
USD |
NASDAQ |
Sep 10, 11:12
Tempest Therapeutics Shareholders Equity (Quarterly) : -1.09M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.09M |
| March 31, 2026 | 0.822M |
| December 31, 2025 | 6.668M |
| September 30, 2025 | 6.346M |
| June 30, 2025 | 9.783M |
| March 31, 2025 | 11.13M |
| December 31, 2024 | 19.13M |
| September 30, 2024 | 11.46M |
| June 30, 2024 | 16.94M |
| March 31, 2024 | 20.63M |
| December 31, 2023 | 26.77M |
| September 30, 2023 | -1.19M |
| June 30, 2023 | 5.012M |
| March 31, 2023 | 10.96M |
| December 31, 2022 | 18.11M |
| September 30, 2022 | 26.77M |
| June 30, 2022 | 34.93M |
| March 31, 2022 | 29.36M |
| December 31, 2021 | 36.12M |
| September 30, 2021 | 43.54M |
| June 30, 2021 | 48.11M |
| March 31, 2021 | 24.96M |
| December 31, 2020 | 17.91M |
| September 30, 2020 | 39.15M |
| June 30, 2020 | 44.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 53.83M |
| December 31, 2019 | 58.55M |
| September 30, 2019 | 43.07M |
| June 30, 2019 | 52.97M |
| March 31, 2019 | 61.52M |
| December 31, 2018 | |
| September 30, 2018 | 44.91M |
| June 30, 2018 | 50.21M |
| March 31, 2018 | 57.33M |
| December 31, 2017 | 64.30M |
| September 30, 2017 | 72.29M |
| June 30, 2017 | 81.14M |
| March 31, 2017 | 94.72M |
| December 31, 2016 | 108.22M |
| September 30, 2016 | 129.88M |
| June 30, 2016 | 146.56M |
| March 31, 2016 | 108.84M |
| December 31, 2015 | 126.85M |
| September 30, 2015 | 142.59M |
| June 30, 2015 | 156.71M |
| March 31, 2015 | 169.09M |
| December 31, 2014 | 55.32M |
| September 30, 2014 | 68.62M |
| June 30, 2014 | 78.70M |
| March 31, 2014 | 86.40M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 9.633M |
| Total Liabilities (Quarterly) | 10.72M |
| Debt to Equity Ratio | -6.936 |
| Current Ratio | 0.3813 |
| Net Debt Paydown Yield | 6.25% |